CREBBP/EP300 acetyltransferase inhibition disrupts FOXA1-bound enhancers to inhibit the proliferation of ER+ breast cancer cells.

CREBBP/EP300 acetyltransferase inhibition disrupts FOXA1-bound enhancers to inhibit the proliferation of ER+ breast cancer cells.

Therapeutic targeting of the estrogen receptor (ER) is a clinically validated approach for estrogen receptor positive breast cancer (ER+ BC), but sustained response is limited by acquired resistance. Targeting the transcriptional coactivators required for estrogen receptor activity represents an alt...

Full description

Bibliographic Details
Main Authors: Archana Bommi-Reddy, Sungmi Park-Chouinard, David N Mayhew, Esteban Terzo, Aparna Hingway, Michael J Steinbaugh, Jonathan E Wilson, Robert J Sims, Andrew R Conery
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0262378

Internet

https://doi.org/10.1371/journal.pone.0262378

Similar Items